The proportion of pregnancies occurring in women of at least 35 years of age has increased from 6.2% in 1980 to 22.3% of births in 2016. This review summarizes recent epidemiological and basic scientific studies investigating the association between older maternal age and adverse pregnancy outcome(s), and clinical studies which investigate the effects of intervention to reduce adverse events.
INTRODUCTION
In the United Kingdom, there has been a focus on reducing the number of stillbirths, neonatal deaths, maternal deaths and brain injuries occurring at or soon after birth, with a specific aim to reduce these adverse events by half by 2025. Although the origins of these events are complex and multifactorial there is overlap between risk factors which are associated with these adverse outcomes. One maternal factor which is associated with adverse outcomes for infants and mothers is maternal age. Although the definition of advanced maternal age (AMA) varies, it is widely defined as maternal age more than 35 years of age [1] . Epidemiological studies, the most recent of which will be reviewed in this article, have described an association between maternal age at least 35 years of age and foetal and maternal mortality and morbidity. This relationship is of particular importance because the proportion of pregnancies occurring in this group of women in the United Kingdom has increased steadily from 6.2% in 1980 to 22.3% of births in 2016 ( Fig. 1) [2] . This trend has been replicated in many high-income countries including those in Western Europe, North America and Australia [3] [4] [5] [6] . The reasons for the change towards delayed childbearing are complex and beyond the scope of this review, but include the availability of safe, effective contraception, access to education and career and to be in a stable relationship with a supportive partner. More prevalent use of artificial reproductive techniques (ART) may also account for a proportion of the increase in births in this age group [7] . This review will summarize recent The risk of adverse outcomes increases with maternal age and interacts with other risk factors for example medical comorbidities to further increase the risk for women and their babies.
Intervention by IOL at 39-week gestation is not associated with increased risk of Caesarean section, is economically sustainable and would reduce perinatal mortality. mediate some of the increased risk of stillbirth. Due to its size, this systematic review also explored the relationship between factors which could account for the increased risk of stillbirth in women at least 35 years; these included maternal comorbidities (e.g. obesity, diabetes, hypertension) and the use of ART. Only maternal hypertension was correlated with stillbirth in women over the age of 35, suggesting that maternal age is an independent risk factor for stillbirth [8 && ]. Although this meta-analysis was able to provide clear evidence of the association between stillbirth and maternal age at least 35 years, it was not able to determine the origins of this increased risk. Earlier studies identified that stillbirths in women over the age of 35 more frequently occur in late pregnancy, with an apparent shift in the increased stillbirth rate seen at 41 weeks in younger women (one in 1333) to 40 weeks in women at least 35 years of age (one in 735) [9 & ]. A study of 637 stillbirths occurring in women over the age of 35 found that in this population stillbirths were more commonly due to major congenital anomalies [relative risk ratio (RRR) 2.0, 95% CI 1.3-3.0], mechanical causes (RRR 1.6), maternal disorders (RRR 2.1, 95% CI 1.2-3.6), and associated obstetric factors (RRR 2.1, 95% CI 1.1-3.9) [10] . On the contrary, this study employed the classification system employed by Centre for Maternal and Child Enquiries, using which results in a high proportion of deaths (29%) with no relevant factors identified, in part because this classification system had no means to record foetal growth restriction (FGR) or placental conditions as a cause for stillbirth, both of which are important risk factors. The association of maternal age at least 35 years with conditions which are strongly associated with placental disorders, such as small for gestational age (SGA) infants and preeclampsia, raises the possibility that AMA could be associated with increased risk of stillbirth by placental dysfunction.
The relationship between maternal age at least 35 years and other adverse foetal outcomes was also explored in the systematic review by Lean et al., although there were fewer studies exploring these outcomes. Meta-analysis defined an increased risk of SGA (OR 1.16, 95% CI 1.06-1.27; 25 studies of 11] . As this meta-analysis pooled data from observational studies, it is possible AMA is linked to adverse foetal outcome(s) by confounding factors which were not measured by this analysis. Significantly, women over the age of 35 are more likely to have higher levels of education, higher income, and are more likely to be employed and attend prenatal classes, all of which reduce the risk of adverse pregnancy outcomes [12, 13] . Thus, despite these favourable characteristics, AMA still appears to be an independent risk factor for adverse foetal outcome(s).
RELATIONSHIP BETWEEN ADVANCED MATERNAL AGE AND ADVERSE MATERNAL OUTCOMES
The relationship between maternal age and maternal mortality has been explored in international studies, which demonstrate a nonlinear increase in the maternal mortality ratio with maternal age, with the highest maternal mortality rates in women in the oldest age groups [14, 15] . A UK case-control study of 105 maternal deaths identified factors which were significantly associated with maternal deaths in women at least 35 years compared with those less than 35 years of age; these were: cigarette smoking during pregnancy [adjusted OR (aOR) 2.1, 95% CI 1.1-3.8], inadequate use of antenatal care (aOR 23.6, 95% CI 8.8-63.5), medical comorbidities (aOR 5.9, 95% CI 3.6-9.9) and previous pregnancy complications (aOR 2.1, 95% CI 1.2-3.5) [16 & ]. In this study, the odds of maternal death increased by 12% per year increase in age. Comorbidities that were highlighted in cases of maternal death were cardiac disease, hypertension, infection, musculoskeletal disorders, asthma, mental health disorders and neurological diseases [16 & ]. Importantly, the greater number of risk factors for maternal mortality that were present, the greater the risk of maternal mortality (one risk factor OR 2.8, 95% CI 1. . Foetal : placental weight ratio is decreased in SGA and FGR pregnancies, which is thought to result from increased placental size in an attempt to increase nutrient transfer to the foetus [18] [19] [20] . At a microscopic level, trophoblast proliferation is reduced and the presence of syncytial nuclear aggregates (also termed syncytial knots) is increased [17 & ]. These changes are also seen in postterm pregnancies and in FGR stillbirths [21] [22] [23] , thus these observations are consistent with a hypothesis of accelerated placental ageing in mothers at least 35 years of age, which could explain the increased risk of stillbirth from 40-week gestation seen at 42-week gestation in women less than 35 years of age [9 & ]. Ageing is a complex process involving oxidative stress and inflammation. Preliminary data suggest that women at least 35 years of age with normal pregnancy outcomes have increased total antioxidant capacity, decreased anti-inflammatory cytokines (IL-10 and IL-1RA) and increased proinflammatory cytokines (IFN-g, TNF-a, IL-8 and IL-1a) in their blood compared with women aged 20-30 years, whereas those mothers at least 35 with adverse outcomes have increased evidence of oxidative stress and a further reduction in anti-inflammatory cytokines [24] .
The effect of AMA has been explored in two animal models (mouse and rat). There are important similarities in pregnancy outcome in these models and pregnancy outcome in women at least 35 years of age with increased foetal loss rate and high levels of FGR. Both rodent models of AMA had larger placentas and lower foetal : placental weight ratios [17 & , 25, 26] . There were also some changes in vascular behaviour with the mouse model showing increased endothelial-dependent relaxation in AMA and there was increased myogenic responses in systematic and uterine arteries in AMA rats [17 & ,26] . AMA mice also showed reduced uterine artery remodelling during pregnancy compared with young controls [27] . There was also reduced placental amino-acid transport in the AMA mouse model compared with young mice which indicates a reduction in placental efficiency [17 & ]. These findings support the human data, suggesting that abnormal placental function is evident in AMA. Further research is needed to determine the origins of the observed reduction of placental function, and whether it is amenable to therapeutic intervention.
INTERVENTION STUDIES IN MOTHERS OF ADVANCED MATERNAL AGE
As women have an increased risk of adverse foetal and maternal outcome, particularly stillbirth in late pregnancy, consideration has been given to whether women at least 35 years of age should have additional antenatal surveillance and earlier birth advised [28] . The increased incidence of FGR has led to the recommendation that maternal age at least 40 years should be considered an indication for regular assessment of foetal growth in late pregnancy and women aged at least 35 years should have this in the presence of other risk factors for FGR [29] . Consideration should also be given to screening for gestational diabetes and hypertensive disorders of pregnancy. Various studies report that earlier delivery is currently offered to women at least 35 years [30, 31] ; a survey published in 2012 found that 37% of obstetricians offered induction of labour (IOL) at term to women aged 40-44, rising to 55% for women aged at least 45 [30] . This practice raised concerns that this intervention could precipitate an increase in Caesarean section or instrumental vaginal births as women at least 35 years of age have an increased risk of these procedures [32] . In nulliparous women, there is a linear association between maternal age and birth by emergency Caesarean section [32] . This concern was addressed by the 35-39 trial, a randomized controlled trial of IOL at 39 þ 0-39 þ 6-week gestation compared with expectant management. The primary outcome of this trial was Caesarean section, which did not differ between the two groups with 98/304 in the induction group and 103/314 in the expectant management group (relative risk 0.99, 95% CI 0.87-1.14) [33 && ]. There was also no difference in the incidence of the secondary outcomes (including: placental abruption, postpartum haemorrhage, Apgar score less than 7 at 5 min, admission to neonatal intensive care unit) between groups. This trial concluded that IOL in women at least 35 years of age at 39-week gestation was not associated with a change in the rate of Caesarean section or adverse maternal or neonatal outcomes [33
&&
]. A cost-utility analysis performed alongside the trial based upon quality of life measures and estimates of resource use found that IOL at 39 weeks was associated with a costsaving of £263 [34] .
There were no stillbirths amongst participants of the 35-39 trial, which was unsurprising as there were 619 participants, and the trial was not statistically powered to investigate a change in stillbirth rate. However, the potential effect of IOL in nulliparous women at least 35 years of age was compared with expectant management using routinely collected data from English hospitals between 2009 and 2014. This analysis of 77 327 women, 33% of whom had IOL, found IOL at 40-week gestation was associated with a lower incidence of in hospital perinatal death compared with women who had expectant management (0.08 vs. 0.26% (adjusted risk ratio, aRR 0.33, 95% CI 0. 13 The study used routinely collected data to demonstrate that IOL at 40 weeks of pregnancy in women aged 35 years or over was associated with a reduction in perinatal mortality before discharge from hospital and a reduction in meconium aspiration syndrome. There were small increases in Caesarean section and instrumental delivery in women who had an IOL.
